drugset / Trial / NCT02023606

Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M

NCT02023606 ↗

Phase 1 Completed 7 enrolled Supernus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers

Timeline

Start
2013-11
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SPN-810M Unknown 50 mg —